MAXION
Live / Registered — Registered (as of 07 Apr 2026)
What this means for you
Registered since 07 Apr 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 07 Apr 2032: the §71 affidavit of use).
Record
- Serial number
- 79412149
- Registration number
- 8200209
- Mark type
- Word mark
- Filed
- 07 Oct 2024
- Published for opposition
- 17 Feb 2026
- Registered
- 07 Apr 2026
- Next maintenance filing
- §71 affidavit of use, due by 07 Apr 2032 (grace period to 07 Oct 2032)
- Attorney of record
- Ben Natter
Goods and services
- Class 001 — Chemicals: Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
- Class 005 — Pharmaceuticals: Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human vaccine preparations
- Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
- Class 044 — Medical, beauty and agricultural services: Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Owner
Prosecution history
- 01 Oct 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 13 Sept 2026 — FINAL DISPOSITION NOTICE SENT TO IB
- 13 Sept 2026 — FINAL DISPOSITION PROCESSED
- 07 Jul 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 28 May 2026 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 11 May 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 11 May 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 07 Apr 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Apr 2026 — REGISTERED-PRINCIPAL REGISTER
- 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Feb 2026 — PUBLISHED FOR OPPOSITION
- 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Jan 2026 — EXAMINER'S AMENDMENT ENTERED
- 27 Jan 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED